Expert perspectives on recent evolutions with CDK4/6 inhibitors in the HR+, HER2- metastatic breast cancer treatment landscape.
EP. 1: Evolving Treatment Landscape of HR+/HER2- Metastatic Breast Cancer
EP. 2: HR+/HER2- Metastatic Breast Cancer: Treatment Armamentarium
EP. 3: Factors in Selecting Frontline Therapy for HR+/HER2- Metastatic Breast Cancer
EP. 4: PALOMA-2 and PALOMA-3: Time to Chemotherapy on Palbociclib + Endocrine Therapy
EP. 5: MONALEESA-2 and MONALEESA-3: Frontline Ribociclib + Endocrine Therapy
EP. 6: MONARCH 2 and MONARCH 3: Pooled Analysis of Abemaciclib + Fulvestrant
EP. 7: HR+/HER2- Metastatic Breast Cancer: Selecting From Approved CDK4/6 Inhibitors
EP. 8: Importance of Molecular Testing in HR+/HER2- Metastatic Breast Cancer
EP. 9: HR+/HER2- Metastatic Breast Cancer: Real-World Data on CDK4/6 Inhibitors
EP. 10: Mechanisms of Resistance to CDK4/6- and ER-Targeted Therapy in Metastatic BC
EP. 11: Overcoming Resistance in HR+/HER2- mBC: Novel ADC and SARM Therapy
EP. 12: Overcoming Resistance in HR+/HER2- mBC: Other Novel Targeted Agents
EP. 13: Addressing Unmet Needs in HR+/HER2- Metastatic Breast Cancer
EP. 14: HR+/HER2- Breast Cancer: Excitement for Upcoming Clinical Trial Readouts
Zanubrutinib May Be Viable Option After Acalabrutinib Intolerance in B-Cell Malignancies
Pelabresib/Ruxolitinib Combo Improves Splenomegaly, TSS in JAK Inhibitor–Naive Myelofibrosis
Tisagenlecleucel Yields Durable Responses in R/R Follicular Lymphoma
Ruxolitinib Shows Sustained Efficacy Over Best Available Therapy in Steroid-Refractory/Dependent cGVHD